Beijing Novel Pharm Co., Ltd.

Primary objective To compare the differences in the extent and rate of absorption of tadalafil tablets (specification: 20 mg) provided by Beijing Huicheng Ruixiang Pharmaceutical Biotechnology Co., Ltd. and tadalafil tablets (specification: 20 mg; trade name: Cialis®) licensed by Eli Lilly Nederland B.V. in healthy adult males under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary objective To evaluate the safety of tadalafil tablets (specification: 20 mg) provided by Beijing Huicheng Ruixiang Pharmaceutical Biotechnology Co., Ltd. and tadalafil tablets (specification: 20 mg; trade name: Cialis®) licensed by Eli Lilly Nederland B.V. under fasting and postprandial administration conditions.

Primary objective: Using gliclazide sustained-release tablets (specification: 60 mg) provided by Beijing Huicheng Ruixiang Pharmaceutical Biotechnology Co., Ltd. as the test preparation and gliclazide sustained-release tablets (trade name: Diamecon) (specification: 60 mg) produced by Les Laboratoires Servier Industrie, France as the reference preparation, according to the provisions of relevant bioequivalence studies, the differences in absorption degree and absorption rate between the two preparations were compared in healthy adult subjects in China, and the bioequivalence of the two preparations was investigated. Secondary objective: To observe the safety and tolerability of the test preparation gliclazide sustained-release tablets and the reference preparation gliclazide sustained-release tablets (trade name: Diamecon) in healthy adult subjects in China.

To evaluate the efficacy and safety of compound omeprazole capsules (omeprazole 40 mg/sodium bicarbonate 1100 mg) in the treatment of active gastric ulcer